Red Herring has been selecting the most exciting and promising start-ups and “scale ups” since 1995. Finalists are evaluated individually from a large pool of hundreds of candidates based across North America. Twenty major criteria underlie the scoring and process. Each company goes through an individual interview after filling out a thorough submission, complemented by a due diligence process. The list of finalists often includes the best performing and prominent companies of that year.

“The finalists list confirms the excellent choices made by entrepreneurs and VCs and the start-ups’ solid roots in corporate America, embracing their innovations. By all metrics, it emphasizes the United States’ entrepreneurial excellence,” said Alex Vieux, publisher and CEO of Red Herring.

Finalist elections for the 2013 edition of the Red Herring 100 North America award are based upon technological innovation, management strength, market size, investor record, customer acquisition and financial health. During the several months leading up to the announcement, hundreds of companies in the fields of security, Web 2.0, software, hardware, life sciences, cloud, mobile and others completed their submissions to qualify for the award.

“We are honored to be named a Top 100 finalist and be among so many distinguished companies that are on the forefront of innovation,” said Lissa Goldenstein, president and CEO of Auxogyn Inc. “Auxogyn is committed to advancing the field of reproductive health. Our goal in developing the Eeva™ Test is to help patients achieve a successful pregnancy. The availability of new innovations, such as the Eeva Test, can help IVF clinics optimize the treatment path for their patients who are undergoing IVF procedures.”

About IVF

Infertility affects one out of every eight couples in the United States. The demand for assisted reproduction tools and procedures is growing worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. This worldwide growth is occurring despite the significant cost per IVF cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.

About the Early Embryo Viability Assessment (Eeva) Test

The Eeva Test is designed to improve embryo selection by providing clinicians with objective information to more confidently select embryo(s) for transfer to help achieve better IVF outcomes. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters discovered by researchers at Stanford University. The Eeva test not only provides novel quantitative information, but also ensures consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures. The effectiveness of the Eeva Test was validated in a prospective, multi-center, 54-patient clinical trial with 758 embryos. Embryologists using Eeva were significantly able to improve their ability to identify non-viable embryos relative to traditional methods. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

Eeva is currently CE Mark approved and available for use only in the EU and is pending FDA clearance in the United States. For more information about Eeva, visit eevaivf.com or follow Eeva on Twitter @EevaIVF.

About Auxogyn

Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com and follow us on Twitter @Auxogyn.

“As the world’s first IVF clinic, we are proud to be one of the first clinics in the world to offer the Eeva Test, further enhancing the likelihood of a positive outcome for our patients,” said Martyn Blayney, head of science at Bourn Hall. “The Eeva Test enables us to not only see the embryo during the early developmental stages, but also gives us a result on the developmental potential of the embryo based on factual, objective scientific evidence, not just on how the embryos look. This is something that has not been available until now and has the potential to truly change the way we select embryos.”

“Our goal in developing the Eeva test is to help couples achieve a successful pregnancy. With the expansion of Eeva throughout the UK, more couples will now have access to the first and only non-invasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “We’ve seen great success from the clinics in the UK and Ireland already offering the Eeva Test and now couples in the East England area can also benefit from this new technology.”

Appointments for the new test are available from Bourn Hall by calling + 44 (0)1954 719111. Visit http://www.bourn-hall-clinic.co.uk/ for further details.

About IVF

Infertility affects one out of every six couples in the UK. The demand for assisted reproduction tools and procedures is growing worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. This worldwide growth is occurring despite the significant cost per IVF cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.

About the Early Embryo Viability Assessment (Eeva) Test
The Eeva Test is designed to improve embryo selection by providing clinicians with objective information to more confidently select embryo(s) for transfer to help achieve better IVF outcomes. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters discovered by researchers at Stanford University in the United States. The Eeva test not only provides novel quantitative information, but also ensures consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures. The effectiveness of the Eeva Test was validated in a prospective, multi-center, 54-patient clinical trial with 758 embryos. Embryologists using Eeva were significantly able to improve their ability to identify non-viable embryos relative to traditional methods. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

Eeva is currently CE Mark approved and available for use only in the EU and is pending FDA clearance in the United States. For more information about Eeva, visit eevaivf.com or follow Eeva on Twitter @EevaIVF.

About Auxogyn
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com and follow us on Twitter @Auxogyn.

###

Media Contact:
Jessica Volchok
BrewLife
(310) 774-3423
jvolchok@brewlife.com

“Kathryn is a valuable addition to our board with her extensive experience in the field of women’s reproductive health and leadership in growing early stage companies to successful enterprises. Kathryn was the first CEO of Conceptus and under her leadership, the company rapidly grew to be a worldwide leader in bringing innovative solutions to the field of women’s reproductive health,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “Her experience will be instrumental in this next stage for Auxogyn, as we continue to expand the commercialization of our flagship product, the Eeva™ Test, which is currently available throughout the UK and Ireland.”

Ms. Tunstall has served as chairman of the Board of Directors of Conceptus, Inc., since January 2000 and as a member of the company’s Board of Directors since her appointment as CEO in July 1993. Prior to joining Conceptus, she was employed by Edwards Less Invasive Surgery Division of Baxter International, where she held a number of positions including president. Earlier in her career, she held various positions in finance, operations and marketing at American Hospital Supply Corporation. Ms. Tunstall also served as a director and compensation committee chair of Caliper LifeSciences, a publicly-traded biotechnology company, until its acquisition by Perkin Elmer, Inc. in November, 2011. She holds a B.A. in economics from the University of California and has completed graduate-level studies in business and healthcare administration.

“With one in six couples experiencing infertility, there is a tremendous need for technology to improve outcomes in order to help couples achieve their dream of having a healthy child. I’m pleased to be joining the Board of Directors at Auxogyn,” said Kathryn Tunstall. “The Eeva Test brings a technological breakthrough to in vitro fertilization (IVF), offering objective information to clinical teams to predict which embryos are the most viable and ultimately, to help patients increase their odds for success.”

About the Eeva™ Test

Auxogyn’s non-invasive Early Embryo Viability Assessment (Eeva) Test is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select the best embryo(s) for transfer. Eeva provides quantitative and objective information on the early stages of the embryo’s development and predicts the viability of each embryo. Eeva’s proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters. With Eeva, IVF clinics may be able to optimize the treatment path for their patients undergoing IVF procedures. The Eeva Test is CE Mark approved and is available in clinics throughout the United Kingdom and Ireland. In the United States, the Eeva Test is pending 510K clearance and is limited to investigational use only. For more information regarding Eeva, please visit eevaivf.com or follow on Twitter @ EevaIVF.

About Auxogyn

Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com or follow on Twitter @Auxogyn.

# # #

Contact:
Nicole Foderaro
BrewLife
(415) 946-1058
nfoderaro@brewlife.com

– Sims IVF is First Clinic in Ireland to Offer the Eeva Test – 

– Eeva Designed to Improve IVF Outcomes by Assessing Embryo Viability With a New Level of Accuracy –

MENLO PARK, Calif. – January 24, 2013 – Auxogyn Inc. today announced that Sims IVF is the first fertility clinic in Ireland to offer patients the Early Embryo Viability Assessment (Eeva) Test. The Eeva Test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. The Eeva Test uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It is the first and only non-invasive IVF test clinically proven to improve the accuracy of selecting embryos that will likely grow to the blastocyst stage, a critical milestone in embryo development.

“We are proud to be the first clinic in Ireland to offer the Eeva Test, giving our patients the best chance at a successful embryo implantation,” said Dr. David Walsh, director and consultant gynaecologist at Sims IVF. “The Eeva Test is the most significant breakthrough in IVF in recent decades. Since intra-cytoplasmic sperm injection (ICSI) in the early 1990’s, we have been waiting for a new technology that could have a transformative effect on IVF success rates. Eeva allows us to select embryos based on factual, objective scientific evidence, not just on how the embryos look – something that has not been available to us until now.”

“With the expansion of Eeva into Ireland, more patients will now have access to the first and only non-invasive test that delivers consistent, objective and actionable information to help identify viable embryos and determine which ones offer the greatest potential,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “Our goal in developing Eeva is to help patients achieve a successful pregnancy. We expect that the availability of Eeva will help IVF clinics optimize the treatment path for their patients who are undergoing IVF procedures.”

Appointments for the new test are available from Sims IVF by calling 011 353 01 208 0710 or visiting www.sims.ie. Sims IVF is holding Eeva Information evenings on 7 & 13 February 2013 at Sims IVF Clonskeagh. Visit www.sims.ie for further details.

About IVF
Infertility affects one out of every six couples. The demand for assisted reproduction tools and procedures is growing worldwide due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. This worldwide growth is occurring despite the significant cost per cycle and the low success rate, with approximately one-third of cycles resulting in a live birth. This necessitates the transfer of multiple embryos and/or conducting multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved.

About the Early Embryo Viability Assessment (Eeva) Test
The Eeva Test is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select embryo(s) for transfer. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters discovered by Stanford University researchers. The Eeva test not only provides novel quantitative information, but also ensures consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimise the treatment path for their patients undergoing IVF procedures.

The safety and efficacy of Eeva were validated in a prospective, multi-center, 54-patient clinical trial with 755 embryos. Embryologists using Eeva were significantly able to improve their ability to identify non-viable embryos (85 percent of the time vs. 60 percent of the time when using traditional methods). Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

Eeva is currently approved and available for use only in the EU. For more information about Eeva, visit eevaivf.com or follow Eeva on Twitter @EevaIVF.

About Auxogyn
Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that IVF clinicians and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com and follow us on Twitter @Auxogyn.

Contact:
Nicole Foderero
BrewLife
(415) 946-1058
nfoderaro@brewlife.com

– Eeva Designed to Improve IVF Outcomes by Assessing Embryo Viability with a New Level of Accuracy –

LONDON, UK, and MENLO PARK, Calif. – November 02, 2012 –Auxogyn, Inc., a company focused on revolutionising the field of reproductive health, and CRM London, today announced that CRM London is the first infertility clinic in London to offer the Early Embryo Viability Assessment (Eeva) Test to patients undergoing in vitro fertilisation (IVF). Additionally, Auxogyn announced that the Eeva Test will be made available to IVF patients at King’s College Hospital in London, and in the East of England through Bourn Hall Clinic, later this year.

The Eeva Test, developed and marketed by Auxogyn, is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy. Eeva uses intelligent computer vision software to measure key scientifically and clinically validated cell-division parameters from video images. It predicts with high accuracy at the cleavage stage (day 3) which embryos will likely grow to the blastocyst stage (day 5-6), a critical milestone in embryo development.

“We are delighted to be one of the first clinics in the world to offer the Eeva, giving our patients the best chance for successful embryo implantation,” said Robert Forman, medical director of CRM London. “CRM London has been one of the leading IVF clinics in the UK for over a decade. To keep this position we are often early access partners with intelligent technologies. By using Eeva, our laboratory team will be able to help our patients and doctors make more informed decisions about the best embryo to transfer and provide the highest chance of pregnancy.”

Auxogyn will be exhibiting this weekend, 3-4 November, at The Fertility Show, Olympia 2 Exhibition Center, London, where representatives from the company and fertility specialists from CRM London, Bourn Hall Clinic and King’s College Hospital will be available at the Eeva stand to discuss the clinical utility and benefits of the test.

“For patients, IVF can be a stressful time, physically, emotionally and financially. The availability of Eeva across the UK is an important advancement as it can provide more accurate information to help IVF patients and their doctors make informed decisions,” said Clare Lewis-Jones of Infertility Network UK.

“Our goal in developing Eeva is to help infertility patients achieve a successful pregnancy. We are excited to be partnering with these clinics to make Eeva available to IVF patients and their clinicians throughout the greater London area,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “Eeva will help IVF clinics optimise the treatment path for their patients who are undergoing IVF procedures by providing access to the first and only non-invasive test that delivers consistent, objective and actionable information to help identify viable embryos to determine which ones offer the greatest potential for transfer.”

Infertility patients who would like to know more about Eeva should contact CRM London on +44 20 7616 6767, eeva@crmlondon.co.uk, or visit www.eevaivf.com.

About the Eeva™ Test

Eeva is designed to improve IVF outcomes by providing clinicians and patients with objective information that will enable them to more confidently select embryo(s) for transfer. Eeva’s proprietary software automatically analyses embryo development against scientifically and clinically validated cell-division parameters, not only providing novel quantitative information, but also ensuring consistent measurements to assess embryo development versus the manual methods used today in clinical practice. With Eeva’s quantitative data for each embryo’s potential development, IVF clinics may be able to optimise the treatment path for their patients undergoing IVF procedures.

The safety and efficacy of Eeva were validated in a prospective, multi-centre, 160-patient clinical trial, results of which were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey. In the study, Eeva was able to predict blastocyst formation at the cleavage stage with 85 percent specificity, reducing the false positive rate from 43 percent to 15 percent compared with traditional morphology selection. Eeva also demonstrated the ability to track and analyse cell division timings with greater than 90 percent accuracy. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists.

Eeva is currently approved and available for use only in the EU.

About IVF

Infertility affects one of seven couples, or 3.5 million people, in the UK[i] — many of whom try to conceive through IVF. The demand for assisted reproduction tools and procedures is growing by 5.9 percent per year in the UK, due to higher infertility rates caused by an increasing maternal age as more women are starting families later in life. The demand is growing despite the significant cost per cycle — £4000 to £8000 in the UK — and the fact that only approximately one-third of cycles result in a live birth. This can lead to multiple cycles, leading to greater physical, emotional, practical and financial costs, before determining if pregnancy can be achieved. 

About CRM London

Established in 1997, CRM is one of London’s leading independent IVF clinics. Its staff of 25 specialist doctors, embryologists, fertility nurses and counsellors, provide over 1000 cycles of treatment per year ranging from basic infertility diagnosis through to the latest cutting-edge technologies including embryo genetic screening and egg freezing as well as egg and sperm donation. Many of London’s leading fertility doctors choose to run their practices from CRM London. For further information, please visit www.crmlondon.co.uk

About Auxogyn

Auxogyn is revolutionising the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company’s flagship product, the Eeva™ Test, delivers consistent, objective and quantitative information regarding embryo viability that reproductive endocrinologists and infertility patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information regarding Auxogyn, please visit www.auxogyn.com.

Follow us on Twitter @auxogyn: http://twitter.com/auxogyn

Like us on Facebook

View our videos on YouTube

Contact:

Elizabeth Marshall-Evans

WCG

0203 116 6479

emarshallevans@wcgworld.com

Lauren Friedman

WCG

0203 116 6485

lfriedman@wcgworld.com